Technical Analysis for MPSYF - Morphosys Ag

Grade Last Price % Change Price Change
grade A 125.96 -10.44% -14.6900
MPSYF closed down 10.44 percent on Friday, August 7, 2020, on 6.8 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical MPSYF trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -10.44%
Wide Bands Range Expansion -10.44%
Gapped Up Strength -10.44%
Overbought Stochastic Strength -10.44%
Older signals for MPSYF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer�s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.Over 70 therapeutic antibody programs based on the company�s technologies are currently in development, of which 20 are in clinical trials. The company�s most advanced proprietary program is MOR103, a first-in-class antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR208 and MOR202, both for the treatment of cancer.MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Medicine Healthcare Medical Specialties Cancer Pharmaceutical Industry Immunology Antibodies Treatment Of Cancer Healthcare Products Drug Development Multiple Sclerosis Rheumatoid Arthritis Antibody Monoclonal Antibodies Antibody Technology Monoclonal Antibody Therapy

Is MPSYF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 142.85
52 Week Low 36.63
Average Volume 7,485
200-Day Moving Average 97.8672
50-Day Moving Average 116.7079
20-Day Moving Average 113.8907
10-Day Moving Average 123.1970
Average True Range 6.1430
ADX 16.7
+DI 49.7310
-DI 44.4172
Chandelier Exit (Long, 3 ATRs ) 122.2210
Chandelier Exit (Short, 3 ATRs ) 106.1990
Upper Bollinger Band 143.3521
Lower Bollinger Band 84.4293
Percent B (%b) 0.7
BandWidth 51.7363
MACD Line 4.7533
MACD Signal Line 1.5945
MACD Histogram 3.1588
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 126.1100
Resistance 3 (R3) 126.0933 126.0267 126.0850
Resistance 2 (R2) 126.0267 125.9885 126.0350 126.0767
Resistance 1 (R1) 125.9933 125.9649 126.0100 126.0100 126.0683
Pivot Point 125.9267 125.9267 125.9350 125.9350 125.9267
Support 1 (S1) 125.8933 125.8885 125.9100 125.9100 125.8517
Support 2 (S2) 125.8267 125.8649 125.8350 125.8433
Support 3 (S3) 125.7933 125.8267 125.8350
Support 4 (S4) 125.8100